MicroPulse™ transscleral cyclophotocoagulation in the treatment of canine glaucoma: Preliminary results (12 dogs)

Abstract

<p>Objective: To describe the clinical application and effect of MicroPulse™ transscleral cyclophotocoagulation (MP‐TSCPC) in dogs with glaucoma.</p> <p>Animals studied: Twelve dogs with primary (n = 8) or secondary (n = 4) glaucoma, aged 2‐13 years (mean ± SD, 7.2 ± 3.8 years).</p> <p>Procedures: MP‐TSCPC was performed under sedation or general anesthesia. Laser duty cycle was 31.3%, laser power varied from 2000‐2800 mW, and each hemisphere was treated for 90‐180 seconds. The probe was applied to each quadrant in a “sweeping motion,” sparing the 3 and 9 o'clock positions.</p> <p>Results: The number of MP‐TSCPC procedures per eye varied from 1 to 3 (1.4 ± 0.7). Intraocular pressure (IOP) was controlled (<25 mm Hg) in 11/12 dogs (92%) within 1‐15 days post‐operatively. The IOP control at 1 month and the duration between repeated procedures were significantly greater in eyes treated with high energy laser (2800 mW) compared to 2000‐2500 mW. Long‐term follow‐up (315.3 ± 100.7 days) showed controlled IOP in 5/12 (42%) and vision retention in 4/8 (50%) dogs. In unsuccessful cases, loss of IOP control or vision loss occurred within 3‐245 days (109.1 ± 93.7 days) and 28‐261 days (114 ± 101.6 days), respectively, resulting in a salvage procedure in 6 dogs. Complications were as follows: corneal hypoesthesia (92%), anterior uveitis (67%), post‐operative ocular hypertension (50%), neurotrophic corneal ulcer (25%), keratoconjunctivitis sicca (8%), and rubeosis iridis (8%).</p> <p>Conclusions: MP‐TSCPC is a viable tool for managing canine glaucoma, although further studies are required to improve the long‐term effect and reduce the complication rate.</p>